Edgewise Therapeutics shares rise 39.3% on positive early results for heart treatment EDG-7500 in Phase 1 and 2 trials.

Edgewise Therapeutics (NASDAQ: EWTX) shares rose 39.3% to $26.58 following positive early results for its heart treatment EDG-7500, designed for obstructive hypertrophic cardiomyopathy (HCM). In Phase 1 and Phase 2 trials, the drug showed significant reductions in left ventricular outflow tract pressure gradients and NT-proBNP levels, indicating heart failure improvement, with no adverse effects on vital signs or left ventricular function. Further data is expected in early 2025.

September 19, 2024
7 Articles

Further Reading